Poseida Therapeutics' P/S ratio remains modest despite the r...

Poseida Therapeutics' P/S ratio remains modest despite the recent stock price surge. With inferior revenue forecasts and expected revenue decline, it's unlikely for a significant increase in share price in the near future.